Goldman Sachs analyst Andrea Tan initiated coverage of Arrowhead Pharmaceuticals with a Neutral rating and $31 price target. Arrowhead is a near-commercial stage company leveraging its proprietary TRiM platform to develop RNAi therapies across various disease indications, the analyst tells investors in a research note. The firm sees the company’s key value drivers as emerging likely in 202 and beyond, starting with plozasiran SHASTA registrational studies and the Phase 2b ARO-RAGE data in asthma.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue